avibactam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 4946 1192500-31-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • NXL-104
  • avibactam
  • NXL104
  • AVE1330A
  • avibactam sodium
a non-beta-lactam beta-lactamase inhibitor that inactivates some beta-lactamases and protects ceftazidime from degradation by certain beta-lactamases
  • Molecular weight: 265.24
  • Formula: C7H11N3O6S
  • CLOGP: -1.63
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 130.24
  • ALOGS: -1.25
  • ROTB: 3

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.24 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.76 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.93 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 2015 FDA CEREXA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 60.08 55.39 37 337 379804 46305884

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pathogen resistance 160.71 71.43 38 710 8372 29943358
Drug resistance 89.65 71.43 29 719 20104 29931626
Septic shock 81.92 71.43 37 711 63570 29888160

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000000202 beta Lactamase Inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pyelonephritis indication 45816000 DOID:11400
Infectious disease of abdomen indication 128070006
Bacterial urinary infection indication 312124009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.64 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS Feb. 25, 2020 NEW CHEMICAL ENTITY
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS Feb. 25, 2025 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-lactamase Enzyme INHIBITOR Kd 8.15 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR Kd 8.70 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-lactamase Enzyme INHIBITOR Kd 6.18 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
7352665165 UNII
D10340 KEGG_DRUG
4034342 VUID
N0000191549 NUI
1192491-61-4 SECONDARY_CAS_RN
4034342 VANDF
C1527648 UMLSCUI
CHEBI:85984 CHEBI
FYG PDB_CHEM_ID
CHEMBL1689063 ChEMBL_ID
CHEMBL2107817 ChEMBL_ID
DB09060 DRUGBANK_ID
9835049 PUBCHEM_CID
8972 INN_ID
C543519 MESH_SUPPLEMENTAL_RECORD_UI
10761 IUPHAR_LIGAND_ID
1603833 RXNORM
30974 MMSL
d08357 MMSL
015925 NDDF
015926 NDDF
715180004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AVYCAZ HUMAN PRESCRIPTION DRUG LABEL 2 0456-2700 POWDER, FOR SOLUTION 0.50 g INTRAVENOUS NDA 28 sections